KR970705394A - AN OINTMENT PREPARATION - Google Patents

AN OINTMENT PREPARATION

Info

Publication number
KR970705394A
KR970705394A KR1019970701067A KR19970701067A KR970705394A KR 970705394 A KR970705394 A KR 970705394A KR 1019970701067 A KR1019970701067 A KR 1019970701067A KR 19970701067 A KR19970701067 A KR 19970701067A KR 970705394 A KR970705394 A KR 970705394A
Authority
KR
South Korea
Prior art keywords
ointment
guanine
hydroxymethyl
content
bis
Prior art date
Application number
KR1019970701067A
Other languages
Korean (ko)
Inventor
가즈오 오쓰키
지카라 고무로
유키오 아오다
유키오 이리에
Original Assignee
다께다 가즈히코
닛폰 가야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다께다 가즈히코, 닛폰 가야쿠 가부시키가이샤 filed Critical 다께다 가즈히코
Publication of KR970705394A publication Critical patent/KR970705394A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

9-[(1R,2R,3S)-2,3-비스(히드록시메틸)시클로부탄-1-일]구아닌과 유지성 기제를 필수 성분으로 함유하고, 9-[(1R,2R,3S)-2,3-비스(히드록시메틸)시클로부탄-1-일]구아닌의 분말이 유지성 기제 중에 균일히 분산되어 있는 것을 특징으로 하는 연고제, 예컨대, 9-[(1R,2R,3S)-2,3-비스(히드록시메틸)시클로부탄-1-일]구아닌의 함유량이 0.05%∼10%이고, 유지성 기제의 함유량이 40%∼99.5%이며, 필요에 따라 피부에 대한 친화성 부여제로서의 계면 활성제와 연고 기제로서의 물을 함유해도 좋다. 이 연고제는 국소 투여를 위한 항바이러스제로서 유용하여 우수한 치료효과를 나타낸다.9 - [(1R, 2R, 3S) -2,3-bis (hydroxymethyl) cyclobutan-1-yl] guanine and a retention base, (1R, 2R, 3S) -2, 3-bis (hydroxymethyl) cyclobutane-1-yl] guanine is uniformly dispersed in a retentive base, (Hydroxymethyl) cyclobutane-1-yl] guanine is 0.05% to 10%, the content of the retentive base is 40% to 99.5%, and if necessary, But may contain an activator and water as an ointment base. This ointment agent is useful as an antiviral agent for topical administration and exhibits excellent therapeutic effects.

Description

연고제(AN OINTMENT PREPARATION)AN OINTMENT PREPARATION

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is a trivial issue, I did not include the contents of the text.

Claims (9)

9-[(1R,2R,3S)-2,3-비스(히드록시메틸)시클로부탄-1-일]구아닌과 유지성기제를 함유학, 9-[(1R,2R,3S)-2,3-비스(히드록시메틸)시클로부탄-1-일]구아닌의 분말이 연고기제 중에 균일하게 분산되어 있는 것을 특징으로 하는 연고제.9 - [(1R, 2R, 3S) -2,3-dihydroxy-9- [ -Bis (hydroxymethyl) cyclobutane-1-yl] guanine is uniformly dispersed in the ointment base. 청구항 1에 있어서, 연고제 중에서의 9-[(1R,2R,3S)-2,3-비스(히드록시메틸)시클로부탄-1-일]구아닌의 함유량이 0.05∼10%인 연고제.The ointment according to claim 1, wherein the content of 9 - [(1R, 2R, 3S) -2,3-bis (hydroxymethyl) cyclobutan-1-yl] guanine in the ointment is 0.05 to 10%. 청구항 1에 있어서, 연고제 중에서의 9-[(1R,2R,3S)-2,3-비스(히드록시메틸)시클로부탄-1-일]구아닌의 함유량이 0.5∼3%인 연고제.The ointment according to claim 1, wherein the content of 9 - [(1R, 2R, 3S) -2,3-bis (hydroxymethyl) cyclobutan-1-yl] guanine in the ointment is 0.5 to 3%. 청구항 1, 청구항 2 또는 청구항 3에 있어서, 유지성 연고 기제가 겔화 탄화수소인 연고제.The ointment agent according to claim 1, 2, or 3, wherein the retentive ointment base is a gelled hydrocarbon. 청구항1, 청구항 2 또는 청구항 3에 있어서, 계면 활성제를 함유하고, 연고제 중에서의 계면 활성제의 함유량이 50% 이하인 연고제.The ointment agent according to claim 1, 2, or 3, wherein the ointment agent contains a surfactant and the content of the surfactant in the ointment agent is 50% or less. 청구항 5에 있어서, 물을 함유하고, 연고제 중에서의 물의 함유량이 50%이하인 연고제.The ointment according to claim 5, wherein the ointment agent contains water and the content of water in the ointment agent is 50% or less. 9-[(1R,2R,3S)-2,3-비스(히드록시메틸)시클로부탄-1-일]구아닌(화합물A), 유지성 기제 및 필요에 따라 계면 활성제와 물을 함유하고, 연고제 전체에 대해 이들 성분의 함유량이 아래와 같은 연고제.(Compound A), a retention base and, if necessary, a surfactant and water, and the total amount of the ointment agent The content of these components is as follows. 화합물 A 0.05∼10%Compound A 0.05 to 10% 유지성 기제 99.95∼40%Retention mechanism 99.95 ~ 40% 계면활성제 0∼50%Surfactants 0-50% 물 0∼50%Water 0 to 50% 청구항 7에 있어서, 전체에 대해 각 성분의 함유량이 아래와 같은 연고제.The ointment agent according to claim 7, wherein the content of each component relative to the whole is the following. 화합물 A 0.05∼10%Compound A 0.05 to 10% 유지성 기제 99.95∼50%Retention mechanism 99.95 ~ 50% 계면활성제 0∼30%Surfactants 0-30% 물 0∼30%Water 0 to 30% 계면 활성제와 물을 실직적으로 함유하지 않고, 9-[(1R,2R,3S)-2,3-비스(히드록시메틸)시클로부탄-1-일]구아닌을 0.5%∼3% 및 유지성 기제를 99.5∼97%함유하는 연고제.(1R, 2R, 3S) -2,3-bis (hydroxymethyl) cyclobutan-1-yl] guanine in an amount of 0.5% to 3% Of an ointment containing 99.5 to 97%. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: It is disclosed by the contents of the first application.
KR1019970701067A 1994-09-06 1995-08-23 AN OINTMENT PREPARATION KR970705394A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP94-236032 1994-09-06
JP23603294 1994-09-06
PCT/JP1995/001670 WO1996007414A1 (en) 1994-09-06 1995-08-23 Ointment

Publications (1)

Publication Number Publication Date
KR970705394A true KR970705394A (en) 1997-10-09

Family

ID=16994756

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701067A KR970705394A (en) 1994-09-06 1995-08-23 AN OINTMENT PREPARATION

Country Status (4)

Country Link
EP (1) EP0780126A1 (en)
KR (1) KR970705394A (en)
CN (1) CN1157563A (en)
WO (1) WO1996007414A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863560A (en) * 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
CN106798364A (en) * 2017-01-21 2017-06-06 浙江百寿堂药业有限公司 A kind for the treatment of chilblain gloves lining cloth

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723609A (en) * 1988-03-30 1998-03-03 E. R. Squibb & Sons, Inc. Bis (hydroxymethyl) cyclobutyl purines
JP2577640B2 (en) * 1988-09-09 1997-02-05 日本化薬株式会社 New cyclobutane derivatives

Also Published As

Publication number Publication date
CN1157563A (en) 1997-08-20
WO1996007414A1 (en) 1996-03-14
EP0780126A1 (en) 1997-06-25

Similar Documents

Publication Publication Date Title
KR960028918A (en) Topical pharmaceutical composition
DK0722313T3 (en) Viscoelastic compositions of fluorinated organic compounds
KR950005319A (en) Pharmaceutical composition
RU93005176A (en) LIQUID ANTIBACTERIAL COMPOSITION
DE69123795D1 (en) Pharmaceutical composition for rectal administration of active ingredients with topical medicinal effects in the colon level
BR9810729A (en) Pharmaceutical composition for acidic lipophilic compounds arranged as a self-emulsifying formulation
KR950007857A (en) Rapamycin preparations for oral administration
KR910005876A (en) Minimal pharmaceutical compositions for the treatment of capillary weakness
OA07525A (en) Amino-acid derivatives, their preparation and use as well as the compositions containing these derivatives.
BR9810711A (en) Topical formulation of antipruritic spray, and, process for prevention or treatment of itching in a patient
KR970705394A (en) AN OINTMENT PREPARATION
KR890006639A (en) Benzothiazine dioxide derivatives
ES2059869T3 (en) PHARMACEUTICAL PREPARATION CONTAINING PIROXICAM FOR TOPICAL USE.
KR950031084A (en) Topical Jinyang Composition
AU6922891A (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
KR840002250A (en) Efficient Combination of Gels with Different Activity Levels
KR970073583A (en) Pharmaceutical composition for injection containing turk
FI946057A (en) Preparation for topical use
KR910021238A (en) Keloid Remedy
GB9522885D0 (en) Improvements in or relating to organic compositions
ATE35620T1 (en) PHARMACEUTICAL PREPARATION WITH RETARDED EFFECT.
KR960003717A (en) Use of elliprodil and its enantiomers for the manufacture of a medicament useful for the prevention of peripheral neuropathy caused by anticancer agents
BR9916524A (en) Topical pharmaceutical formulation, use of acyclovir, dimethicone and water-miscible polyhydric alcohol, and process for the treatment of viral infection
KR890009396A (en) Percutaneous Absorption Formulation
KR980000432A (en) Cosmetic composition containing serine

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid